HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.

Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising therapeutic target for treating coronary heart disease. We report a novel antibody 1B20 that binds to PCSK9 with sub-nanomolar affinity and antagonizes PCSK9 function in-vitro. In CETP/LDLR-hemi mice two successive doses of 1B20, administered 14 days apart at 3 or 10 mpk, induced dose dependent reductions in LDL-cholesterol (≥ 25% for 7-14 days) that correlated well with the extent of PCSK9 occupancy by the antibody. In addition, 1B20 induces increases in total plasma antibody-bound PCSK9 levels and decreases in liver mRNA levels of SREBP-regulated genes PCSK9 and LDLR, with a time course that parallels decreases in plasma LDL-cholesterol (LDL-C). Consistent with this observation in mice, in statin-responsive human primary hepatocytes, 1B20 lowers PCSK9 and LDLR mRNA levels and raises serum steady-state levels of antibody-bound PCSK9. In addition, mRNA levels of several SREBP regulated genes involved in cholesterol and fatty-acid synthesis including ACSS2, FDPS, IDI1, MVD, HMGCR, and CYP51A1 were decreased significantly with antibody treatment of primary human hepatocytes. In rhesus monkeys, subcutaneous (SC) dosing of 1B20 dose-dependently induces robust LDL-C lowering (maximal ~70%), which is correlated with increases in target engagement and total antibody-bound PCSK9 levels. Importantly, a combination of 1B20 and Simvastatin in dyslipidemic rhesus monkeys reduced LDL-C more than either agent alone, consistent with a mechanism of action that predicts additive effects of anti-PCSK9 agents with statins. Our results suggest that antibodies targeting PCSK9 could provide patients powerful LDL lowering efficacy on top of statins, and lower cardiovascular risk.
AuthorsLiwen Zhang, Timothy McCabe, Jon H Condra, Yan G Ni, Laurence B Peterson, Weirong Wang, Alison M Strack, Fubao Wang, Shilpa Pandit, Holly Hammond, Dana Wood, Dale Lewis, Ray Rosa, Vivienne Mendoza, Anne Marie Cumiskey, Douglas G Johns, Barbara C Hansen, Xun Shen, Neil Geoghagen, Kristian Jensen, Lei Zhu, Karol Wietecha, Douglas Wisniewski, Lingyi Huang, Jing Zhang Zhao, Robin Ernst, Richard Hampton, Peter Haytko, Frances Ansbro, Shannon Chilewski, Jayne Chin, Lyndon J Mitnaul, Andrea Pellacani, Carl P Sparrow, Zhiqiang An, William Strohl, Brian Hubbard, Andrew S Plump, Daniel Blom, Ayesha Sitlani
JournalInternational journal of biological sciences (Int J Biol Sci) Vol. 8 Issue 3 Pg. 310-27 ( 2012) ISSN: 1449-2288 [Electronic] Australia
PMID22355267 (Publication Type: Journal Article)
Chemical References
  • Antibodies, Monoclonal
  • Anticholesteremic Agents
  • CETP protein, human
  • Cholesterol Ester Transfer Proteins
  • Cholesterol, LDL
  • RNA, Messenger
  • Receptors, LDL
  • Recombinant Proteins
  • Sterol Regulatory Element Binding Proteins
  • Simvastatin
  • PCSK9 protein, human
  • Pcsk9 protein, mouse
  • Proprotein Convertase 9
  • Proprotein Convertases
  • Serine Endopeptidases
Topics
  • Animals
  • Antibodies, Monoclonal (pharmacology, therapeutic use)
  • Antibody Affinity
  • Anticholesteremic Agents (administration & dosage, therapeutic use)
  • Cells, Cultured (drug effects, metabolism)
  • Cholesterol Ester Transfer Proteins (genetics, metabolism)
  • Cholesterol, LDL (blood)
  • Gene Expression Profiling
  • Gene Expression Regulation (drug effects)
  • Hep G2 Cells (drug effects, metabolism)
  • Hepatocytes (drug effects, metabolism)
  • Humans
  • Immunization, Passive
  • Lipid Metabolism (genetics)
  • Liver (drug effects, metabolism)
  • Macaca mulatta
  • Metabolic Syndrome (drug therapy, genetics, therapy)
  • Mice
  • Mice, Transgenic
  • Proprotein Convertase 9
  • Proprotein Convertases (antagonists & inhibitors, biosynthesis, genetics, immunology)
  • RNA, Messenger (metabolism)
  • Receptors, LDL (biosynthesis, genetics)
  • Recombinant Proteins (metabolism)
  • Serine Endopeptidases (biosynthesis, genetics, immunology)
  • Simvastatin (administration & dosage, therapeutic use)
  • Sterol Regulatory Element Binding Proteins (physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: